이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Simulations Plus 미래 성장

Future 기준 확인 4/6

Simulations Plus은 연간 수입과 매출이 각각 26.6%와 17.8% 증가할 것으로 예상되고 EPS는 연간 25.4%만큼 증가할 것으로 예상됩니다.

주요 정보

26.6%

수익 성장률

25.4%

EPS 성장률

Healthcare Services 수익 성장	26.9%
매출 성장률	17.7%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	28 Jun 2024

최근 미래 성장 업데이트

Recent updates

Simulations Plus: Questionable Whether It Will Benefit Or Be Hurt By Generative AI

Feb 01

We Like Simulations Plus' (NASDAQ:SLP) Earnings For More Than Just Statutory Profit

Jan 12

Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal

Nov 06

Estimating The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)

Sep 06

Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Jun 28

Some Investors May Be Worried About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Feb 10

With EPS Growth And More, Simulations Plus (NASDAQ:SLP) Makes An Interesting Case

Nov 23

A Look At The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)

Oct 21

Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Sep 19

Simulations Plus goes ex-dividend tomorrow

Jul 21

Simulations Plus Q3 2022 Earnings Preview

Jul 05

Simulations Plus (NASDAQ:SLP) Might Be Having Difficulty Using Its Capital Effectively

Jun 08

Estimating The Fair Value Of Simulations Plus, Inc. (NASDAQ:SLP)

Mar 02

Simulations Plus: Software For The Pharma Industry, Significant Upside Potential

Mar 01

This Is Why We Think Simulations Plus, Inc.'s (NASDAQ:SLP) CEO Might Get A Pay Rise Approved By Shareholders

Feb 05

수익 및 매출 성장 예측

NasdaqGS:SLP - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
8/31/2026	105	19	22	32	3
8/31/2025	92	16	16	25	4
8/31/2024	71	11	9	15	4
2/29/2024	65	11	13	18	N/A
11/30/2023	62	11	13	17	N/A
8/31/2023	60	10	18	22	N/A
5/31/2023	56	10	22	27	N/A
2/28/2023	54	10	18	22	N/A
11/30/2022	53	11	15	19	N/A
8/31/2022	54	12	14	18	N/A
5/31/2022	52	12	14	18	N/A
2/28/2022	50	12	14	19	N/A
11/30/2021	48	10	12	17	N/A
8/31/2021	46	10	15	19	N/A
5/31/2021	46	12	12	16	N/A
2/28/2021	46	11	10	14	N/A
11/30/2020	43	10	11	14	N/A
8/31/2020	42	9	8	11	N/A
5/31/2020	40	9	6	9	N/A
2/29/2020	38	9	8	10	N/A
11/30/2019	36	9	10	12	N/A
8/31/2019	34	9	10	12	N/A
5/31/2019	33	8	10	12	N/A
2/28/2019	31	7	9	11	N/A
11/30/2018	30	9	7	9	N/A
8/31/2018	30	9	7	9	N/A
5/31/2018	29	9	6	8	N/A
2/28/2018	27	8	7	9	N/A
11/30/2017	26	6	N/A	8	N/A
8/31/2017	24	6	N/A	7	N/A
5/31/2017	22	5	N/A	7	N/A
2/28/2017	21	5	N/A	6	N/A
11/30/2016	21	5	N/A	8	N/A
8/31/2016	20	5	N/A	5	N/A
5/31/2016	20	5	N/A	6	N/A
2/29/2016	20	5	N/A	6	N/A
11/30/2015	19	4	N/A	7	N/A
8/31/2015	18	4	N/A	7	N/A
5/31/2015	17	4	N/A	6	N/A
2/28/2015	14	3	N/A	5	N/A
11/30/2014	13	3	N/A	4	N/A
8/31/2014	11	3	N/A	5	N/A
5/31/2014	11	3	N/A	4	N/A
2/28/2014	10	3	N/A	4	N/A
11/30/2013	10	3	N/A	4	N/A
8/31/2013	10	3	N/A	3	N/A

애널리스트 미래 성장 예측

수입 대 저축률: SLP 의 연간 예상 수익 증가율( 26.6% )이 saving rate( 2.4% 보다 높습니다. ).

수익 vs 시장: SLP 의 연간 수익( 26.6% ) US 시장( 14.9% 보다 빠르게 성장할 것으로 예상됩니다. 14.9% 연간).

고성장 수익: SLP 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: SLP 의 수익(연간 17.8% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: SLP 의 수익(연간 17.8% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: SLP 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Simulations Plus 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 12% to US$60.33

Simulations Plus, Inc. Reiterates Earnings Guidance for the Fiscal Year 2024

Price target decreased by 9.1% to US$53.33

Price target decreased by 12% to US$55.00

Price target decreased to US$59.75

Recent updates

Now 12% overvalued after recent price rise

Now 21% overvalued after recent price rise

Simulations Plus, Inc. to Report Q3, 2024 Results on Jul 02, 2024

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 12% to US$60.33

Simulations Plus, Inc. (NasdaqGS:SLP) acquired Pro-ficiency, LLC from NovaQuest Capital Management, L.L.C., QHP Capital, L.P. and Pro-ficiency’s minority shareholders for approximately $100 million.

Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software

Simulations Plus: Reliance On Consulting And Acquisitions Creates Doubts

lead Independent Director notifies of intention to sell stock

Upcoming dividend of US$0.06 per share

Second quarter dividend of US$0.06 announced

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Now 43% overvalued after recent price rise

Simulations Plus, Inc. Declares a Cash Dividend, Payable on May 6, 2024

Why We're Not Concerned About Simulations Plus, Inc.'s (NASDAQ:SLP) Share Price

Simulations Plus, Inc. to Report Q2, 2024 Results on Apr 03, 2024

Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal

Now 22% overvalued after recent price rise

Simulations Plus: Questionable Whether It Will Benefit Or Be Hurt By Generative AI

Simulations Plus, Inc. Releases GastroPlus Version 9.9

Upcoming dividend of US$0.06 per share at 0.6% yield

We Like Simulations Plus' (NASDAQ:SLP) Earnings For More Than Just Statutory Profit

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

President of PBPK notifies of intention to sell stock

Simulations Plus, Inc., Annual General Meeting, Feb 08, 2024

Simulations Plus, Inc. to Report Q1, 2024 Results on Jan 03, 2024

Simulations Plus, Inc. Reiterates Earnings Guidance for the Fiscal Year 2024

Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal

Price target decreased by 9.1% to US$53.33

Simulations Plus, Inc. Declares Cash Dividend , Payable on November 6, 2023

Simulations Plus, Inc. to Report Q4, 2023 Results on Oct 25, 2023

Simulations Plus Receives New FDA Grant Award

Estimating The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)

Upcoming dividend of US$0.06 per share at 0.5% yield

Simulations Plus, Inc. Releases ADMET Predictor® 11

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Simulations Plus, Inc. Declares Cash Dividend , Payable on August 7, 2023

Co-Founder & Chairman notifies of intention to sell stock

Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Simulations Plus, Inc. to Report Q3, 2023 Results on Jul 06, 2023

Simulations Plus, Inc. (NasdaqGS:SLP) acquired Immunetrics, Inc. from LaunchCyte LLC for $23.5 million.

Price target decreased by 12% to US$55.00

Upcoming dividend of US$0.06 per share at 0.5% yield

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

President exercised options to buy US$1.5m worth of stock.

President notifies of intention to sell stock

Simulations Plus Releases Redesigned NAFLDsym QSP Software Tool

Some Investors May Be Worried About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Upcoming dividend of US$0.06 per share

Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Simulations Plus, Inc. (NasdaqGS:SLP) announces an Equity Buyback for $50 million worth of its shares.

Co-Founder & Chairman notifies of intention to sell stock

Simulations Plus, Inc., Annual General Meeting, Feb 09, 2023

Price target decreased to US$59.75

Simulations Plus, Inc. to Report Q1, 2023 Results on Jan 04, 2023

With EPS Growth And More, Simulations Plus (NASDAQ:SLP) Makes An Interesting Case

High number of new and inexperienced directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Simulations Plus, Inc. Announces Board Changes

Simulations Plus, Inc. Declares Cash Dividend, Payable on November 7, 2022

A Look At The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)

Co-Founder & Chairman exercised options to buy US$1.5m worth of stock.

Simulations Plus Releases GastroPlus® Version 9.8.3

Simulations Plus, Inc. to Report Q4, 2022 Results on Oct 26, 2022

Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Simulations Plus Releases State-Of-The-Art QSP Software for Interstitial Lung Disease

Price target increased to US$65.25

Simulations Plus goes ex-dividend tomorrow